Why Some Brain Cells Resist Neurodegeneration While Others Crumble
Researchers are cracking why certain brain regions succumb to diseases like Alzheimer's and ALS while others stay healthy. By examining what proteins individual cells actually produce—rather than just their genes—scientists are uncovering the cellular vulnerabilities that could guide the next generation of treatments, potentially unlocking new therapeutic targets worth billions in pharmaceutical development.
Originaltitel: Selective Vulnerability to Neurodegenerative Disease: Insights from Cell Type-Specific Translatome Studies
<p>Neurodegenerative diseases (NDs) manifest a wide variety of clinical symptoms depending on the affected brain regions. Gaining insights into why certain regions are resistant while others are susceptible is vital for advancing therapeutic strategies. While gene expression changes offer clues about disease responses across brain regions, the mixture of cell types therein obscures experimental results. In recent years, methods that analyze the transcriptomes of individual cells (e.g., single-cell RNA sequencing or scRNAseq) have been widely used and have provided invaluable insights into specific cell types. Concurrently, transgene-based techniques that dissect cell type-specific translatomes (CSTs) in model systems, like RiboTag and bacTRAP, offer unique advantages but have received less attention. This review juxtaposes the merits and drawbacks of both methodologies, focusing on the use of CSTs in understanding conditions like amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), Alzheimer's disease (AD), and specific prion diseases like fatal familial insomnia (FFI), genetic Creutzfeldt-Jakob disease (gCJD), and acquired prion disease. We conclude by discussing the emerging trends observed across multiple diseases and emerging methods.</p>